FLO11 Antibody

What is FLO11 and why are antibodies against it important in yeast research?

FLO11 is a key flocculin gene in Saccharomyces cerevisiae that encodes cell surface proteins mediating adhesion to various surfaces. These proteins, known as flocculins, play critical roles in cell-cell interactions and adhesion to biotic and abiotic surfaces . FLO11 antibodies are valuable research tools that enable detection, localization, and quantification of Flo11 proteins in various experimental settings.

The importance of FLO11 antibodies stems from the protein's central role in multiple cellular processes. Research has shown that Flo11p is essential for the formation of adhesive nanodomains on the cell surface, which contribute to cell-cell aggregation. Loss of FLO11 function completely abrogates the formation of these nanodomains, as demonstrated in studies with L69 strain . Additionally, FLO11 expression varies significantly between strains, with some laboratory strains like BY4741 not expressing the protein due to mutations in regulatory elements .

How do I select the appropriate FLO11 antibody for my experimental design?

When selecting a FLO11 antibody, consider these critical factors:

• Target region specificity: The FLO11 gene encodes a protein with distinct domains that contribute differently to its function. As shown in research, Flo11p contains multiple regions including N-terminal (A-domain), repetitive regions (RR1 and RR2), and C-terminal domains . Antibodies targeting different regions will yield different experimental outcomes.

• Strain-specific variations: FLO11 sequences vary significantly between yeast strains. For example, the FLO11 gene in L69 strain is 1.06 kbp longer than in BY4741 (5.16 vs. 4.10 kbp) . Ensure your antibody recognizes the specific variant in your strain of interest.

• Fusion protein compatibility: If working with epitope-tagged Flo11p, select antibodies that won't be hindered by the tag position. Studies have successfully used HA tags at position 1015 amino acid residues for Flo11p .

• Application compatibility: Confirm the antibody is validated for your specific application (Western blotting, immunofluorescence, etc.).

What controls should I include when using FLO11 antibodies in immunoblotting?

Proper controls are essential for reliable FLO11 antibody experiments:

When analyzing results, remember that Flo11p levels may vary significantly between strains. For instance, qRT-PCR studies have shown dramatic differences in FLO11 expression between laboratory strains like BY4741 and wild strains like L69 .

How can I accurately detect and differentiate between membrane-bound and secreted forms of Flo11p?

Detecting different forms of Flo11p requires specific experimental approaches:

• Fractionation protocol: Use a reliable fractionation method to separate membrane-bound from secreted Flo11p. Research has shown that Flo11p undergoes shedding, with secreted forms detectable in culture supernatants .

• Secretion profile analysis: Implement a protocol similar to that described by researchers using Flo11p-HA fusions (at position 1015). This involves:

  • Creating an epitope fusion at the genomic locus under control of the endogenous promoter

  • Analyzing both supernatant (S) and pellet (P) fractions via immunoblotting

  • Determining secretion/pellet (S/P) ratios to quantify shedding rates

• Domain-specific detection: Different domains of Flo11p may be processed differently. Experiments with Flo11p variants lacking specific domains (N-terminal, C-terminal, RR1, or RR2) have shown that these domains contribute differently to Flo11p function and localization .

When interpreting results, recognize that genetic manipulation (such as overexpression from a 2μ plasmid under GAL1 promoter) may alter normal Flo11p processing dynamics compared to endogenous expression .

What approaches can address epitope masking issues when using FLO11 antibodies?

Epitope masking is a significant challenge when working with Flo11p due to its complex structure:

• Surface exposure treatment: Use methods that temporarily disrupt cell wall structures without denaturing proteins. This can expose masked epitopes, particularly in regions involved in amyloid formation.

• Domain-specific targeting: Target antibodies to different regions of Flo11p. Research has shown that Flo11p contains multiple domains with different properties - N-terminal (A-domain), repetitive regions (RR1 and RR2), and C-terminal domain . Some domains may be more accessible than others.

• Amyloid disruption approaches: For experiments where Flo11p is involved in amyloid-like structures, consider using amyloid-disrupting agents. Studies have shown that anti-amyloid compounds like thioflavin S can disrupt Flo11p-dependent cell aggregation without affecting non-amyloid mediated interactions .

• Alternative tagging strategies: If standard antibody approaches fail, consider alternative epitope tagging at different positions. Research has successfully used HA tags at position 1015 in Flo11p .

How can I quantitatively assess FLO11 expression at both protein and transcript levels?

A comprehensive approach to FLO11 expression analysis includes:

Research has shown significant variability in FLO11 expression between strains. For example, FLO11 is highly expressed in L69 strain but not expressed in BY4741 due to a non-sense mutation in the FLO8 transcriptional regulator .

What are effective protocols for immunofluorescence localization of Flo11p on the yeast cell surface?

For effective immunofluorescence of Flo11p:

• Cell wall preparation: Optimize fixation to maintain cell wall integrity while allowing antibody access. This is particularly important as Flo11p forms specialized nanodomains on the cell surface .

• Domain-specific detection: Consider which domain of Flo11p you're targeting. Studies have shown that different domains (N-terminal, RR1, RR2, C-terminal) contribute differently to Flo11p's surface organization .

• Amyloid detection correlation: For comprehensive analysis, combine Flo11p immunofluorescence with amyloid detection using dyes like thioflavin S. Research has shown that Flo11p-dependent cell surface nanodomains have amyloid-like properties that can be disrupted by anti-amyloid agents .

• Strain considerations: Include appropriate controls based on strain background. The L69 strain expresses Flo11p and shows surface nanodomains, while BY4741 does not naturally express Flo11p due to regulatory mutations .

A detailed protocol might include:

• Cell fixation with 4% paraformaldehyde

• Mild cell wall digestion with lyticase

• Blocking with BSA

• Primary antibody incubation (anti-Flo11p)

• Fluorophore-conjugated secondary antibody

• Optional co-staining with thioflavin S (5-10 μM) to detect amyloid structures

• Visualization using confocal microscopy

How can I correlate Flo11p localization with amyloid formation on the cell surface?

To correlate Flo11p localization with amyloid formation:

• Dual labeling approach: Combine Flo11p antibody detection with amyloid-specific dyes. Research has demonstrated that anti-amyloid compounds like thioflavin S (at 10 μM) can specifically interact with amyloid-forming regions of Flo11p .

• AFM imaging correlation: Atomic force microscopy (AFM) can detect Flo11p-dependent nanodomains on the cell surface. Studies have shown these nanodomains have two components: high-adhesion force regions (amyloid) and low-adhesion force regions (isolated proteins) .

• Domain-specific analysis: Use variants of Flo11p lacking specific domains to determine their contribution to amyloid formation. Research has shown that:

  • RR2 region is essential for nanodomain formation

  • N-terminal deletion results in loss of high-adhesion component

  • C-terminal deletion creates needle-shaped morphology with low adhesion

  • RR1 deletion results in tiny, disparate patches

• Amyloid disruption assays: Treat cells with anti-amyloid peptides (like VASTTV at 5 μM) or dyes (thioflavin S at 10 μM) and monitor changes in Flo11p localization and function. AFM images have demonstrated complete disruption of adhesion nanodomains after such treatments .

What techniques can distinguish between different allelic variants of FLO11 using antibodies?

Distinguishing between FLO11 allelic variants requires targeted approaches:

• Epitope mapping strategy: Design or select antibodies that target regions with known sequence variations between alleles. For example, the FLO11 gene in L69 strain is 1.06 kbp longer than in BY4741 (5.16 vs. 4.10 kbp) .

• Domain-specific antibodies: Develop antibodies against specific domains that vary between alleles. Research has identified significant differences in the repetitive regions (particularly RR2) between strains that contribute to functional differences .

• Western blot size discrimination: Different FLO11 alleles encode proteins of different sizes. Use high-resolution gels to distinguish between variants. For example, Flo11p from L69 strain would be larger than from BY4741 due to the additional sequence .

• Functional correlation: Combine antibody detection with functional assays. Studies have shown that different Flo11p variants confer different adhesion properties:

  • L69 Flo11p enables formation of adhesive nanodomains

  • BY4741 Flo11p does not form these structures even when expressed

  • Chimeric proteins containing RR2 from L69 in BY background can restore some functions

How do I address non-specific binding issues with FLO11 antibodies in different yeast strains?

Non-specific binding challenges with FLO11 antibodies can be addressed through:

• Strain-specific optimization: Different yeast strains have different cell wall compositions that may affect antibody accessibility and specificity. For example, L69 and BY4741 strains show significant differences in cell surface properties .

• Enhanced blocking protocols: Use strain-specific blocking solutions that account for cell wall differences:

  • 5% BSA with 0.1% Tween-20 for standard applications

  • Additional blocking with non-specific IgG from the same species as the secondary antibody

  • Pre-absorption of antibodies with flo11Δ cell lysates to remove cross-reactive antibodies

• Control strategy: Always include these critical controls:

  • flo11Δ mutants in the same genetic background as your experimental strain

  • Strains expressing Flo11p variants lacking specific domains to identify domain-specific vs. non-specific signals

  • Pre-immune serum controls

• Signal validation: Confirm antibody specificity using complementary approaches:

  • qRT-PCR to confirm FLO11 expression at the transcript level

  • Functional assays (adhesion, aggregation) to correlate with antibody signals

  • Tagged Flo11p constructs (if biologically relevant) for comparison

What are the most common pitfalls when interpreting FLO11 antibody results and how can they be avoided?

Common pitfalls and their solutions include:

• Strain variation misinterpretation: Different yeast strains express different variants of Flo11p or none at all.

  • Solution: Always thoroughly characterize your strain's FLO11 status

  • Example: BY4741 strain doesn't express FLO11 due to a mutation in FLO8 regulator, while L69 highly expresses it

• Domain-specific function confusion: Different regions of Flo11p have distinct functions.

  • Solution: Use domain-specific antibodies or domain deletion controls

  • Evidence: Research shows RR2 region is essential for nanodomain formation, while other domains modify properties

• Amyloid property overlooking: Flo11p forms amyloid-like structures that affect antibody access.

  • Solution: Consider amyloid-disrupting treatments in your protocols

  • Evidence: Anti-amyloid compounds like thioflavin S disrupt Flo11p-dependent aggregation

• Environmental condition variability: FLO11 expression is highly regulated by environmental conditions.

  • Solution: Standardize growth conditions and document them thoroughly

  • Evidence: Expression studies normalize to reference genes (TAF10, UBC6) to account for variation

• Protein processing misinterpretation: Flo11p undergoes complex processing including shedding.

  • Solution: Analyze both cell-associated and secreted fractions

  • Evidence: Studies have established protocols to determine secretion/pellet ratios

How can I reconcile seemingly contradictory results between antibody-based detection and functional assays of FLO11?

Resolving contradictions between antibody detection and functional assays requires:

• Domain-function correlation analysis: Different Flo11p domains contribute to different functions. Research has shown that:

  • RR2 region is essential for nanodomain formation and contributes 75% to cell-cell adhesion

  • N-terminal deletion reduces cell-cell interaction less than RR2 deletion

  • C-terminal and RR1 deletions each reduce aggregation by approximately 50%

• Amyloid-dependent vs. independent functions: Some Flo11p functions depend on amyloid formation while others don't:

  • Cell aggregation in L69 strain is disrupted by thioflavin S

  • Same phenotype in YSWT3α strain is not affected by this treatment

• Expression level vs. protein variant effects: Sometimes contradictions arise from comparing differently expressed variants:

  • BY4741 overexpressing its own FLO11 forms small aggregates

  • BY4741 overexpressing L69 FLO11 forms large aggregates comparable to L69 strain

  • Insertion of RR2 sequence from L69 into BY FLO11 enhances aggregation

• Assay sensitivity differences: Different detection methods have different sensitivities:

  • Western blotting might detect total protein regardless of conformation

  • Functional assays respond only to correctly folded, properly localized protein

  • Microscopy reveals spatial organization that biochemical assays miss

When facing contradictions, systematically investigate these factors using controls that isolate variables: domain mutants, amyloid disruptors, and expression level normalization .

How can FLO11 antibodies be utilized to study amyloid-based adhesion mechanisms in yeast?

FLO11 antibodies offer powerful tools for studying amyloid-based adhesion:

• Direct visualization approaches: Combine antibodies with fluorescent amyloid dyes:

  • Immunofluorescence with anti-Flo11p antibodies

  • Co-staining with thioflavin S (10 μM) which binds to amyloid structures

  • AFM imaging to correlate with nanodomain formation

• Functional disruption studies: Use antibodies to block specific Flo11p domains:

  • Target RR2 region which contains essential amyloid-forming sequences

  • Compare effects with amyloid disruptors like thioflavin S

  • Analyze impact on cell-cell aggregation

• Structural analysis applications: Use antibodies to isolate native Flo11p:

  • Immunoprecipitate intact protein complexes

  • Analyze amyloid formation in vitro

  • Study effects of environmental conditions on amyloid properties

Research has demonstrated that Flo11p forms adhesive nanodomains with amyloid properties on the cell surface that are essential for cell-cell adhesion. These nanodomains show both high-adhesion (amyloid) and low-adhesion (isolated protein) components, and their formation depends on specific amyloid-forming sequences in the RR2 region .

What are effective strategies for using FLO11 antibodies in comparative studies across different yeast strains and species?

For effective cross-strain/species comparative studies:

• Epitope conservation mapping: Identify conserved regions of Flo11p across strains/species:

  • Analyze sequence alignments (as shown in Figure 3—figure supplement 1)

  • Target antibodies to the most conserved regions for cross-strain studies

  • Develop strain-specific antibodies for comparative analysis

• Domain-specific approach: Target functional domains with different degrees of conservation:

  • N-terminal (A-domain) typically shows higher conservation

  • Repetitive regions (RR1 and RR2) often show greater variation

  • Different domains contribute differently to function across strains

• Functional correlation design: Combine antibody detection with standardized functional assays:

  • Cell-cell adhesion quantification (as shown in Figure 6)

  • Biofilm formation capacity

  • Surface hydrophobicity measurements

  • AFM nanomechanical property analysis

• Environmental response protocol: Compare Flo11p expression and localization under standardized conditions:

  • Growth phase standardization (exponential phase)

  • Media composition control (YPD vs. defined media)

  • Environmental stress responses

Research has shown significant variation in FLO11 sequences and functions between strains. For example, L69 FLO11 is 1.06 kbp longer than BY4741 FLO11, and these differences directly impact adhesion properties and nanodomain formation .

How can I design experiments to study the dynamic regulation of FLO11 expression using antibody-based approaches?

To study dynamic FLO11 regulation:

• Time-course experimental design: Monitor Flo11p levels during environmental transitions:

  • Collect samples at defined intervals after stimulus application

  • Process samples consistently for antibody detection

  • Normalize to stable reference proteins (TAF10, UBC6)

• Single-cell analysis protocol: Use flow cytometry or microscopy with FLO11 antibodies:

  • Analyze cell-to-cell variation in Flo11p expression

  • Correlate with cell cycle stage or morphological features

  • Identify subpopulations with different expression patterns

• Reporter system correlation: Combine antibody detection with transcriptional reporters:

  • Compare protein levels (antibody) with transcript dynamics (reporters)

  • Identify post-transcriptional regulation mechanisms

  • Measure response timing differences between transcript and protein

• Regulatory circuit perturbation: Use antibodies to measure Flo11p response to regulator manipulation:

  • FLO8 pathway components (defective in BY4741)

  • Environmental sensing pathways

  • Epigenetic regulators that affect FLO11 silencing

A comprehensive approach would include qRT-PCR for transcript levels, Western blotting for total protein, and immunofluorescence for localization, all performed on samples collected at consistent timepoints after stimulation .